Neurocrine biosciences reports positive phase 2 data for nbi-1065845 in adults with major depressive disorder

Savitri™ study met primary endpoint with statistically significant reduction in montgomery Åsberg depression rating scale ( madrs) total score at day 28 met key secondary endpoints, including statistically significant reduction in madrs score at day 56 nbi-1065845 was generally well-tolerated san diego , april 23, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix), today announced positive topline data for its phase 2 savitri™ study. this randomized, double-blind, placebo-controlled dose-finding study assessed the efficacy and safety of nbi-1065845 in adult subjects with major depressive disorder (mdd).
TAK Ratings Summary
TAK Quant Ranking